Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 83

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 83
---
, that we
may be able to obtain or result in the denial of our patent applications. In addition, if patents that cover our activities are issued
to other companies, there can be no assurance that we would be able to obtain licenses to these patents at a reasonable cost or be able
to develop or obtain alternative technology. If we do not obtain such licenses, we could encounter delays in the introduction of products,
or could find that the development, manufacture or sale of products requiring such licenses could be prohibited. In addition, we could
incur substantial costs in defending ourselves in suits brought against us on patents it might infringe or in filing suits against others
to have such patents declared invalid.

Much of our know-how and technology
may not be patentable. To protect our rights, we plan to require employees, consultants, advisors and collaborators to enter into confidentiality
agreements. There can be no assurance, however, that these agreements will provide meaningful protection for our trade secrets, know-how
or other proprietary information in the event of any unauthorized use or disclosure. Further, our business may be adversely affected by
competitors who independently develop competing technologies, especially if we obtain no, or only narrow, patent protection.

If we fail to protect our intellectual property
rights, our ability to pursue the development of our technologies and products would be negatively affected. 

Our success will depend, in
part, on our ability to obtain patents and maintain adequate protection of our technologies and products. If we do not adequately protect
our intellectual property, competitors may be able to use our technologies to produce and market drugs in direct competition with us and
erode our competitive advantage. Some foreign countries lack rules and methods for defending intellectual property rights and do not protect
proprietary rights to the same extent as the United States. Many companies have had difficulty protecting their proprietary rights in
these foreign countries. We may not be able to prevent misappropriation of our proprietary rights.

We have received, and are
currently seeking, patent protection for numerous compounds and methods of treating diseases. However, the patent process is subject to
numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products by obtaining and
defending patents. These risks and uncertainties include the following: patents that may be issued or licensed may be challenged, invalidated,
or circumvented, or otherwise may not provide any competitive advantage; our competitors, many of which have substantially greater resources
than us and many of which have made significant investments in competing